ChiCTR2500106032 版本V1.0 版本创建时间2025/07/16 10:02:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500106032 

最近更新日期:

Date of Last Refreshed on:

2025-07-16 10:01:54 

注册时间:

Date of Registration:

2025-07-16 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

艾司氯胺酮对老年三叉神经痛患者全身麻醉诱导的临床效果与术后认知及情绪的影响

Public title:

The Clinical Efficacy of Esketamine on General Anesthesia Induction and Its Impact on Postoperative Cognition and Mood

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮对老年三叉神经痛患者全身麻醉诱导的临床效果与术后认知及情绪的影响

Scientific title:

The Clinical Efficacy of Esketamine on General Anesthesia Induction in Elderly Patients with Trigeminal Neuralgia and Its Impact on Postoperative Cognition and Mood

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

方新华 

研究负责人:

方新华 

Applicant:

Fang Xinhua 

Study leader:

Fang Xinhua 

申请注册联系人电话:

Applicant telephone:

+86 187 2099 7901

研究负责人电话:

Study leader's
telephone:

+86 187 2099 7901

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2624580106@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xinhua9251@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江西省南昌市东湖区豫章街道爱国路152号

研究负责人通讯地址:

江西省南昌市爱国路92号

Applicant address:

No. 152, Aiguo Road, Yuzhang Street, Donghu District, Nanchang, Jiangxi

Study leader's address:

No. 92 Aiguo Road, Donghu District, Nanchang,Jiangxi

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江西省人民医院

Applicant's institution:

Jiangxi Provincial People's Hospital

研究负责人所在单位:

江西省人民医院

Affiliation of the Leader:

Jiangxi?Provincial?People's?Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科快2025卫(23)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江西省人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jiangxi Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-03-25 00:00:00

伦理委员会联系人:

甘晨曦

Contact Name of the ethic committee:

Gan Chenxi

伦理委员会联系地址:

江西省南昌市爱国路92号

Contact Address of the ethic committee:

No. 92 Aiguo Road, Donghu District, Nanchang, Jiangxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 791 8689 6297

伦理委员会联系人邮箱:

Contact email of the ethic committee:

253506019@qq.com

研究实施负责(组长)单位:

江西省人民医院

Primary sponsor:

Jiangxi?Provincial?People's?Hospital

研究实施负责(组长)单位地址:

江西省南昌市爱国路92号

Primary sponsor's address:

No. 92 Aiguo Road, Donghu District, Nanchang,Jiangxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江西省

市(区县):

Country:

China

Province:

Jiangxi

City:

单位(医院):

江西省人民医院

具体地址:

江西省南昌市爱国路92号

Institution
hospital:

Jiangxi Provincial People's Hospital

Address:

No. 92 Aiguo Road, Donghu District, Nanchang,Jiangxi

经费或物资来源:

江西省卫生健康委科技计划

Source(s) of funding:

Jiangxi Provincial Health Commission Science and Technology Plan.

研究疾病:

三叉神经痛  

Target disease:

Trigeminal Neuralgia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究就艾司氯胺酮对老年三叉神经痛患者全身麻醉诱导的临床效果与术后认知及情绪的影响展开,旨在缓解并减轻老年患者恐惧、紧张、焦虑情绪,保持机体内环境的稳定,避免神经内分泌系统紊乱,减少患者的围术期并发症,缩短住院时间、促进术后恢复及优化医疗资源使用  

Objectives of Study:

This study investigates the clinical efficacy of esketamine in the induction of general anesthesia for elderly patients with trigeminal neuralgia and its impact on postoperative cognition and mood. The aim is to alleviate and reduce fear, tension, and anxiety in elderly patients, maintain the stability of the internal environment, prevent neuroendocrine system disorders, reduce perioperative complications, shorten hospital stays, promote postoperative recovery, and optimize the use of medical resources.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.美国麻醉医师协会(ASA)分级II或III级, 2.年龄65~80岁; 3.原发性三叉神经痛,没有服用影响自主神经系统功能的药物。

Inclusion criteria

1. American Society of Anesthesiologists (ASA) physical status II or III; 2. aged between 65 and 80 years, 3. diagnosed with primary trigeminal neuralgia, and not taking any medications that affect the function of the autonomic nervous system.

排除标准:

1.继发性三叉神经痛; 2.严重高血压病; 3.糖尿病; 4.严重心肺功能障碍; 5.心律失常; 6.安装心脏起搏器等。 7.参与其他临床研究的患者; 8.无法沟通或者合作; 9.拒绝参与。

Exclusion criteria:

1. Secondary trigeminal neuralgia; 2. Severe hypertension; 3. Diabetes mellitus; 4. Severe cardiopulmonary dysfunction; 5. Arrhythmia; 6. Patients with pacemakers or other implanted cardiac devices; 7. Participation in other clinical studies; 8. Inability to communicate or cooperate; 9. Refusal to participate.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-21 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

The control group

Sample size:

干预措施:

空白对照

干预措施代码:

Intervention:

blank control

Intervention code:

组别:

艾司氯胺酮组

样本量:

30

Group:

Esketamine group

Sample size:

干预措施:

艾司氯胺酮

干预措施代码:

Intervention:

esketamine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江西省 

市(区县):

 

Country:

China

Province:

Jiangxi

City:

单位(医院):

江西省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangxi Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

Cognitive Function

Type:

Secondary indicator

测量时间点:

术前24h、术后12h、术后24h、术后48h

测量方法:

MoCA评分

Measure time point of outcome:

Preoperative 24 hours, postoperative 12 hours, postoperative 24 hours, postoperative 48 hours

Measure method:

MoCA scores

指标中文名:

抑郁症状

指标类型:

主要指标

Outcome:

Depressive symptoms

Type:

Primary indicator

测量时间点:

术后24h、术后48h

测量方法:

HAMD评分

Measure time point of outcome:

Preoperative 24 hours, postoperative 12 hours, postoperative 24 hours, postoperative 48 hours

Measure method:

HAMD scores

指标中文名:

术后不良反应

指标类型:

次要指标

Outcome:

Postoperative adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管活性药物使用次数

指标类型:

次要指标

Outcome:

the frequency of vasoactive drug use

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血氧饱和度

指标类型:

次要指标

Outcome:

SpO2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

mean arterial pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究参与者用随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

The research participants were randomized using a random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲

Blinding:

Single blind study

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究公开发表后半年,邮件联系研究负责人合理获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the publication of the research, contact the research leader via email to obtain reasonable information.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表,二为电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management consist of two components: one is the case report form, and the other is the electronic data capture and management system.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-07-16 10:01:54